Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.54 |
| ▸ | AR | P10275 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697722 | 0.85 | LMNA (0.68) | PARP1ARLMNAFLT1KDR | |
| SCHEMBL4697283 | 0.84 | PARP1 (0.53) | PARP1ARLMNATSHRCYP3A4 | |
| SCHEMBL6608381 | 0.83 | PARP1 (0.54) | PARP1ARLMNAENPP1TSHR | |
| SCHEMBL4697620 | 0.82 | PARP1 (0.50) | PARP1ARLMNAENPP1TSHR | |
| SCHEMBL4702788 | 0.82 | CYP3A4 (0.53) | PARP1ARLMNAENPP1TSHR | |
| SCHEMBL905630 | 0.81 | AR (0.79) | PARP1ARLMNAENPP1TSHR | |
| SCHEMBL4700133 | 0.81 | PARP1 (0.49) | PARP1ARLMNAENPP1TSHR | |
| SCHEMBL4698988 | 0.80 | PARP1 (0.48) | PARP1ARLMNAENPP1TSHR | |
| SCHEMBL6589989 | 0.80 | CYP11B1 (0.53) | PARP1ARLMNAENPP1TSHR | |
| SCHEMBL6610458 | 0.80 | AR (0.58) | PARP1ARLMNAENPP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765313-A2 | COMPOUNDS FOR IMMUNOPOTENTIATION | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002422-A9 | COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORP (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006002422-A2 | COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-6710047-B2 | INHIBIT THE ACTIVITY OF THE VEGF RECEPTOR TYROSINE KINASE AND THE GROWTH OF TUMOURS | NOVARTIS AG (CH) | 2004-03-23 | — | — | US | disclosed |
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2003-10-09 | — | — | US | disclosed |
| US-6514974-B2 | 1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine for example | NOVARTIS AG (CH) | 2003-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | PARP1 3676/4885AR 908/4885LMNA 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.